T1	Participants 99 150	patients with newly diagnosed or recurrent epilepsy
T2	Participants 228 330	patients with untreated, newly diagnosed or recurrent partial and/or generalised tonic-clonic seizures
T3	Participants 835 854	patients on CBZ 600
